dimethyl fumarate / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 27 Diseases   27 Trials   27 Trials   3795 News 
40 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
dimethyl fumarate / Generic mfg.
2014-000254-11: ROLE OF ENDOTHELIAL INFLAMMATION IN DEMYELINATING DISEASES OF THE CENTRAL NERVOUS SYSTEM Screening efter biomarkører til vurdering af prognose og respons på behandling ved multiple sclerose

Ongoing
4
50
Europe
Tecfidera, Tecfiera, Tecfiera
Department of Neurology, Department of Neurology, Odense University Hospital
Mulple Sclerosis Multipel Sklerose
 
 
2017-000559-26: A multicentric, international study in order to compare the effectiveness of fingolimod versus dimethyl-fumarate on patients with Multiple Sclerosis. Studio multicentrico, internazionale volto a confrontare l'efficacia di fingolimod e dimetil-fumarato in pazienti con Sclerosi Multipla

Ongoing
4
1360
Europe
Capsule, hard, Gastro-resistant capsule, hard, GILENYA - 0.5 MG - CAPSULE RIGIDE - USO ORALE - BLISTER DIVISIBILE PER DOSE UNITARIA(PVC/PVDC/ALU) SCATOLA DA 7X1 CAPSULE, TECFIDERA - 240 MG - CAPSULA RIGIDA GASTRORESISTENTE - USO ORALE - BLISTER (PVC/PE/PVDC-PVC ALLUMINIO) - 56 CAPSULE
FONDAZIONE IRCCS ISTITUTO NEUROLOGICO CARLO BESTA, Patient-Centered Outcomes Research Institute
relapsing-remitting multiple sclerosis sclerosi multipla recidivante-remittente, multiple sclerosis sclerosi multipla, Diseases [C] - Nervous System Diseases [C10]
 
 
2017-002634-24: MultipleMS – a study with the aim to accelerate personalised medicine in multiple sclerosis. MultipleMS - en studie med syftet att utveckla precisionsmedicin för multipel skleros.

Ongoing
4
150
Europe
Infusion, Capsule, Tablet, Injection, Mabthera, Tysabri, Tecfidera, Gilenya, Copaxone, Betaferon, Extavia, Avonex, Rebif, Plegridy, Lemtrada, Aubagio
Karolinska Institutet, Department of Clinical Neuroscience, Karolinska Institutet
Newly diagnosed patients with Clinically Isolated Syndrome (CIS) and multiple sclerosis (MS) -both relapsing remitting and primary progressive), Multiple sclerosis (MS) is an autoimmune disorder of the central nervous system (CNS), characterized by repeated episodes of inflammation in the CNS leading to various neurological symptoms., Diseases [C] - Nervous System Diseases [C10]
 
 
2021-003195-13: Importance of monitoring of drugs used in the treatment of multiple sclerosis Význam terapeutického monitorování perorálně podávaných léčiv modifikující průběh choroby (“disease-modifying drugs”) užívaných k léčbě roztroušené sklerózy

Not yet recruiting
4
800
RoW
Aubagio 14MG TBL FLM, Mavenclad 10MG TBL NOB, Tecfidera 240MG CPS ETD, Gilenya 0,5MG CPS DUR, Tablet, Capsule, Aubagio 14MG TBL FLM, Mavenclad 10MG TBL NOB, Tecfidera 240MG CPS ETD, Gilenya 0,5MG CPS DUR
Fakultní nemocnice Ostrava, Fakultní nemocnice Ostrava
multiple sclerosis roztroušená skleróza, multiple sclerosis roztroušená skleróza, Diseases [C] - Nervous System Diseases [C10]
 
 
ChiCTR2000035667: Efficacy and safety study of dimethyl fumarate in adjuvant therapy for biliary atresia

Not yet recruiting
4
240
 
Take a placebo ;Take dimethyl fumarate
Children's Hospital of Fudan University; Children's Hospital of Fudan University, Shanghai Shenkang Hospital Development Center
Biliary Atresia
 
 
NCT05959759: Dimethyl Fumarate Treatment for Intracranial Unruptured Aneurysms.

Not yet recruiting
4
60
RoW
Dimethyl fumarate, Placebo
Beijing Tiantan Hospital, Beijing Neurosurgical Institute, Beijing Chao Yang Hospital, Henan Provincial People's Hospital
Intracranial Aneurysm, Aneurysm, Brain, Inflammation Vascular
12/23
06/24
NCT05658484: A Study of Dimethyl Fumarate (DMF) in Relapsing Forms of Multiple Sclerosis (RMS) Participants in China

Active, not recruiting
4
60
RoW
Dimethyl fumarate, Tecfidera, DMF, BG00012
Biogen
Multiple Sclerosis
04/25
04/25
NCT05514106: MIBG in Aging and Neurologic Disorders

Enrolling by invitation
4
50
US
meta-iodobenzylguanidine (MIBG) (123I), 123I-MIBG, 123I-MIBG scintigraphy
Mayo Clinic
Lewy Body Disease, Dementia, Parkinsonism, Mild Cognitive Impairment, REM Sleep Behavior Disorder
09/25
09/25
DELIVER-MS, NCT03535298: Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS

Active, not recruiting
4
800
Europe, US
Early Highly Effective Therapies Group, Lemtrada (alemtuzumab), Ocrevus (ocrelizumab), Tysabri (natalizumab), Rituxan (rituximab), Kesimpta (ofatumumab), Briumvi (ublituximab), Escalation Therapies Group, Betaseron (beta interferon), Copaxone (glatiramer acetate), Aubagio (teriflunomide), Extavia (beta interferon), Gilenya (fingolimod), Glatopa (glatiramer acetate), Plegridy (beta interferon), Rebif (beta interferon), Tecfidera (dimethyl fumarate), Avonex (beta interferon), Mavenclad (cladribine), Mayzent (siponimod), Vumerity (diroximel fumarate), Zeposia (ozanimod), Bafiertam (monomethyl fumarate), Ponvory (ponesimod)
The Cleveland Clinic, University of Nottingham
Multiple Sclerosis, Relapsing-Remitting
07/27
09/30
ACTRN12607000124437: Safety and Efficacy of BG00012 in Relapsing Remitting Multiple Sclerosis

Recruiting
3
1011
 
Biogen Idec, Biogen Idec
Multiple Sclerosis (Relapsing Remitting)
 
 
2018-001292-21: Disease modifying therapies withdrawal in inactive Secondary Progressive Multiple Sclerosis patients older than 50 years Arrêt des traitements de fond à visée immunologique chez les patients de plus de 50 ans ayant une sclérose en plaques secondairement progressive

Not yet recruiting
3
250
Europe
AVONEX, BETAFERON, EXTAVIA, REBIF, PLEDIGRY, COPAXONE, AUBAGIO, TECFIDERA, GILENYA, TYSABRI, IMUREL, NOVATREX, CELLCEPT, ENDOXAN, L03 AB 08, Concentrate for solution for injection, Powder for solution for injection, Solution for injection, Solution for injection in pre-filled syringe, Tablet, Capsule, Concentrate for solution for infusion
CHU de Rennes, CHU de Rennes
Secondary Progressive Multiple Sclerosis Sclérose en plaques secondairement progressive, Secondary Progressive Multiple Sclerosis Sclérose en plaques secondairement progressive, Diseases [C] - Nervous System Diseases [C10]
 
 
2020-004505-32: Study of efficacy and tolerability of ofatumumab vs. First Line disease modifying treatment (DMT) - physician’s choice in the treatment of newly diagnosed relapsing multiple sclerosis (RMS) patients

Ongoing
3
236
Europe
ofatumumab, Glatiramer acetate, Interferon β-1b, Interferon β-1a, Peginterferon β-1a, Teriflunomide, Dimethyl fumarate, OMB157, Solution for injection in pre-filled pen, Solution for injection in pre-filled syringe, Powder and solution for solution for injection, Solution for injection, Solution for infusion in pre-filled syringe, Coated tablet, Gastro-resistant capsule, soft, Kesimpta
Novartis Pharma AG, Novartis Pharma AG
Multiple Sclerosis Sclérose en plaques, Multiple Sclerosis Sclérose en plaques, Diseases [C] - Nervous System Diseases [C10]
 
 
RECOVERY, NCT04381936 / 2020-001113-21: Randomised Evaluation of COVID-19 Therapy

Checkmark Efficacy and safety data from RECOVERY trial in COVID-19
Jun 2021 - Jun 2021: Efficacy and safety data from RECOVERY trial in COVID-19
Recruiting
3
70000
Europe, RoW
Lopinavir-Ritonavir, Corticosteroid, Hydroxychloroquine, Azithromycin, Convalescent plasma, Tocilizumab, Immunoglobulin, Synthetic neutralising antibodies, REGEN-COV, casirivimab and imdevimab, Aspirin, Colchicine, Baricitinib, Anakinra, Dimethyl fumarate, High Dose Corticosteroid, Empagliflozin, Sotrovimab, Molnupiravir, Paxlovid, nirmatrelvir/ritonavir, Baloxavir Marboxil, Xofluza, Oseltamivir, Tamiflu, Low-dose corticosteroids: Dexamethasone
University of Oxford, UK Research and Innovation, National Institute for Health Research, United Kingdom, Wellcome, Bill and Melinda Gates Foundation, Department for International Development, United Kingdom, Health Data Research UK, Medical Research Council Population Health Research Unit, NIHR Clinical Trials Unit Support Funding, NIHR Health Protection Research Unit in Emerging and Zoonotic Infections, Flu Lab
Severe Acute Respiratory Syndrome
06/26
06/36
STHENOS, NCT04788615 / 2020-004505-32: Open Label Randomized Multicenter to Assess Efficacy & Tolerability of Ofatumumab 20mg vs. First Line DMT in RMS

Active, not recruiting
3
184
Europe
Ofatumumab, OMB157, First line DMT, Glatiramer acetate or Interferon or Peg-Interferon beta-1a or Teriflunomide or Dimethyl fumarate or Diroximel fumarate
Novartis Pharmaceuticals, Novartis Pharma AG
Multiple Sclerosis
10/25
01/26
CONNECT, NCT02283853 / 2013-002318-11: Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Subjects With Relapsing-remitting Multiple Sclerosis (RRMS)

Active, not recruiting
3
156
Europe, Canada, US, RoW
dimethyl fumarate, BG00012, Tecfidera, Interferon β-1a, Avonex
Biogen
Relapsing-Remitting Multiple Sclerosis
09/25
09/25
MIST, NCT03133403 / 2012-004165-41: Hematopoietic Stem Cell Therapy for Inflammatory Multiple Sclerosis Failing Alternate Approved Therapy

Recruiting
2/3
5
Europe
Tecfidera (BG12), Gilenya, fingolimod, Tysabri®, natalizumab, Avonex/Betaseron/Copaxone/Rebif, (Avonex®, Betaseron®, Copaxone®, Rebif®), Hematopoietic stem cell transplantation (HSCT)
Sheffield Teaching Hospitals NHS Foundation Trust
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
12/21
12/21
NCT06513533: Dimethyl Fumarate in Adrenomyeloneuropathy

Recruiting
2/3
40
Europe
Placebo, Dimethyl fumarate, Skilarence, Tecfidera
Pujol, Aurora, M.D., Instituto de Salud Carlos III, Spanish Clinical Research Network - SCReN, Institut d'Investigació Biomèdica de Bellvitge
Adrenomyeloneuropathy Without Cerebral Involvement
03/28
06/28
ACTRN12618000534280: Study to Assess the Efficacy and Safety of Tecfidera in Patients with Amyotrophic Lateral Sclerosis - TEALS Study

Not yet recruiting
2
90
 
University of Sydney, FightMND
Amyotrophic Lateral Sclerosis
 
 
ACTRN12608000644369: A Phase 2a, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety, and tolerability of BG00012 when given with methotrexate to subjects with active rheumatoid arthritis who have had an inadequate response to conventional disease-modifying anti-rheumatic drug therapy.

Not yet recruiting
2
150
 
Biogen Idec, Inc, Biogen Idec, Inc
Rheumatoid arthritis
 
 
2017-003386-10: Dimethylfumarate for the treatment of Palmoplantar Pustulosis Dimethylfumarat in der Behandlung der Palmoplantaren Pustulose

Ongoing
2
25
Europe
Skilarence, EMEA/H/C/002157, Gastro-resistant tablet, Skilarence 30 mg, Skilarence 120 mg
Medical University of Vienna, Almirall
Palmoplantar Pustulosis Palmoplantare Pustulose, Palmoplantar Pustulosis Palmoplantare Pustulose, Diseases [C] - Skin and Connective Tissue Diseases [C17]
 
 
MS200527-0086, NCT02975349 / 2016-001448-21: A Study of Efficacy and Safety of M2951 in Participants With Relapsing Multiple Sclerosis

Terminated
2
267
Europe, RoW
Evobrutinib, M2951, Placebo, Tecfidera
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Relapsing-remitting Multiple Sclerosis
01/18
04/24
haojunwei5, NCT04891497: Combination of the Immune Modulator Dimethyl Fumarate With Intraarterial Treatment in Acute Ischemic Stroke

Withdrawn
2
50
NA
Dimethyl Fumarate, Placebo
Xuanwu Hospital, Beijing
Acute Ischemic Stroke
12/21
12/21
haojunwei2, NCT04890379: Dimethyl Fumarate for the Treatment of Intracerebral Hemorrhage

Withdrawn
2
50
RoW
Dimethyl fumarate, Placebo
Xuanwu Hospital, Beijing
Intracerebral Hemorrhage
12/21
12/21
LADIGAGA, NCT04292080: Long-Term Analysis of DImethyl Fumarate, to Slow the Growth of Areas of Geographic Atrophy

Recruiting
2
60
Europe
Dimethyl Fumarate (TECFIDERA™), No active : no treatment
Assistance Publique - Hôpitaux de Paris
Age-related Macular Degeneration (AMD)
10/25
10/27
2022-002171-11: Safety and efficacy of dimethyl fumarate in tratment of dementia due to Alzheimer's Disease Skuteczność i bezpieczeństwo fumaranu dimetylu w leczeniu otępienia w chorobie Alzheimera

Not yet recruiting
2
100
Europe
dimethyl fumarate, Gastro-resistant capsule, hard
Medical University of Łódź, Medical Research Agency
dementia and mild cognitice impairment due to Alzheimer's Disease demencja i łagodne zaburzenia poznawcze w Chorobie Alzheimera, dementia and mild cognitice impairment due to Alzheimer's Disease demencja i łagodne zaburzenia poznawcze w Chorobie Alzheimera, Psychiatry and Psychology [F] - Behaviours [F01]
 
 
haojunwei3, NCT04890366: Combination of the Immune Modulator Dimethyl Fumarate With Alteplase in Acute Ischemic Stroke

Recruiting
1/2
50
RoW
Dimethyl Fumarate
Xuanwu Hospital, Beijing
Acute Ischemic Stroke
12/22
12/22
haojunwei4, NCT04890353: Impact of an Immune Modulator Dimethyl Fumarate on Acute Ischemic Stroke

Terminated
1/2
2
RoW
Dimethyl fumarate
Xuanwu Hospital, Beijing
Acute Ischemic Stroke
02/23
02/23
IMCY-MS-001, NCT05417269: IMCY-0141 Safety and Efficacy in Multiple Sclerosis - ISEMIS Study

Active, not recruiting
1/2
150
RoW
IMCY-0141, Imotope, Placebo, Dimethyl Fumarate, DMF
Imcyse SA
Multiple Sclerosis, Relapsing-Remitting
05/25
12/25
CPE, NCT05762003: Czech Pharmaco-epidemiological Study on Disease Modifying Drugs

Completed
N/A
17478
RoW
interferons, glatiramer acetate, teriflunomide, dimethyl fumarate, alemtuzumab, cladribine, fingolimod, ponesimod, rituximab, ocrelizumab, ofatumumab, natalizumab
IMPULS Endowment Fund
Multiple Sclerosis
12/21
12/21
NCT06385197: Improving the Effect of Multiple Sclerosis Drugs by Chronobiology

Completed
N/A
8
RoW
App randomizing dosing regimen
Hadassah Medical Organization
Multiple Sclerosis
06/23
06/23
TEC-ADHERE, NCT04221191: Dimethyl Fumarate (DMF, Tecfidera®) Persistence in RR-MS Patients Included in the French Patient Support Program OroSEP

Completed
N/A
353
Europe
Dimethyl Fumarate, Tecfidera®, PSP
Biogen
Multiple Sclerosis, Relapsing-Remitting
09/22
09/22
NCT05811949: Effects of Dimethyl Fumarate on Cognitive Performance and Brain Abnormalities in Multiple Sclerosis.

Recruiting
N/A
52
Europe
Dimethyl Fumarate 240 MG [Tecfidera]
IRCCS Centro Neurolesi "Bonino-Pulejo"
Multiple Sclerosis
10/22
02/25
ESTEEM, NCT02047097: Dimethyl Fumarate (DMF) Observational Study

Completed
N/A
5487
Europe, Canada, US, RoW
dimethyl fumarate, Tecfidera, DMF, BG00012
Biogen
Multiple Sclerosis
10/22
10/22
COMBAT-MS, NCT03193866 / 2016-003587-39: COMparison Between All immunoTherapies for Multiple Sclerosis.

Active, not recruiting
N/A
3526
Europe
Rituximab, Natalizumab, Fingolimod, Alemtuzumab, Interferon-beta, Glatiramer acetate, Dimethyl Fumarate
Karolinska Institutet, Patient-Centered Outcomes Research Institute, Kaiser Foundation Research Institute
Relapsing-remitting Multiple Sclerosis
12/22
12/22
NCT04468165: Effectiveness and Safety of Generic Delayed-Release Dimethyl Fumarate (Sclera® or Marovarex ®, Hikma) in Routine Medical Practice in the Treatment of Relapsing-Remitting Multiple Sclerosis in MENA Region

Completed
N/A
160
RoW
Dimethyl Fumarate (DMF), Sclera ®, Hikma, Marovarex ®, Hikma
Hikma Pharmaceuticals LLC
Relapsing Remitting Multiple Sclerosis
07/23
07/23
DOT-MS, NCT04260711: Discontinuing Disease-modifying Therapies in Stable Relapsing - Onset Multiple Sclerosis ().

Recruiting
N/A
130
Europe
DMT, Interferon, Glatiramer acetate, Dimethylfumarate, Teriflunomide
VU University Medical Center
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive
08/23
01/24
TREAT-MS, NCT03500328: Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial

Recruiting
N/A
900
US
Natalizumab, Alemtuzumab, Ocrelizumab, Rituximab, Cladribine, Ofatumumab, Ublituximab-xiiy, Tysabri, Lemtrada, Ocrevus, Rituxan, Mavenclad, Kesimpta, Briumvi, Glatiramer acetate, Interferons (intramuscular, subcutaneous, pegylated) Teriflunomide, Fumarates (dimethyl, diroximel, monomethyl) Fingolimod, Siponimod, Ozanimod, Ponesimod, Copaxone, Glatopa, Avonex, Betaseron, Extavia, Rebif, Plegridy, Aubagio, Tecfidera, Vumerity, Bafiertam, Gilenya, Mayzent, Zeposia, Ponvory, Tascenso
Johns Hopkins University, Patient-Centered Outcomes Research Institute, National Multiple Sclerosis Society
Multiple Sclerosis, Relapsing-Remitting
08/25
08/25
STATURE, NCT04676204: Relationship Between Oral DMT Burden and Adherence in MS

Enrolling by invitation
N/A
323
RoW
Cladribine, Mavenclad, Dimethyl fumarate, Tecfidera, Fingolimod, Gilenya, Teriflunomide, Aubagio, Ozanimod, Zeposia, Diroximel fumarate, Vumerity
Monash University
Multiple Sclerosis, Adherence, Medication
11/25
07/26
NCT05658497: Pregnancy Exposure Registry for Vumerity (Diroximel Fumarate)

Recruiting
N/A
908
Europe, US
Diroximel Fumarate, VUMERITY, BIIB098, Avonex, BG9418, interferon beta-1a, Tysabri, Natalizumab, BG00002, Dimethyl Fumarate, Tecfidera, DMF, BG00012
Biogen
Multiple Sclerosis
07/32
07/32
NCT05767736: A Study to Evaluate Long-Term Safety of Vumerity and Tecfidera in Participants With Multiple Sclerosis (MS)

Active, not recruiting
N/A
10500
US
Diroximel Fumarate, VUMERITY, BIIB098, Dimethyl Fumarate, Tecfidera, DMF, BG00012, Disease-Modifying Therapies (DMTs)
Biogen
Multiple Sclerosis
12/32
12/32

Download Options